Police get epinephrine kits to treat allergic emergencies—with federal liability shield
H.R. 4019 — Gio’s Law · Filed by Laura Gillen (D-NY) · 9 cosponsors · Introduced Jun 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a federal grant program allowing the Attorney General to fund state and local law enforcement agencies to purchase epinephrine auto-injectors and train officers to recognize and treat anaphylactic shock. It requires the Attorney General to develop standardized training within 180 days, mandates that states certify legal liability protection for officers before receiving grants, authorizes $25 million annually through 2030, and directs the Justice Department to publish annual data on law enforcement epinephrine use and run a public awareness campaign.
Why we flagged it
The bill's operative mechanism is a straightforward federal grant program to equip and train law enforcement for emergency medical response. It is a public-health measure delivered through law enforcement infrastructure, not a commemorative or vanity bill despite bearing a person's name.
What the text implies
- Liability protection requirement (section 3063) may incentivize states to adopt broad immunity statutes for law enforcement, potentially extending beyond epinephrine administration to other police conduct.
- Annual reporting requirement creates a new federal data collection on law enforcement medical interventions, establishing precedent for federal oversight of police medical practices.
The full analysis lists 4 implications of this text.
Who stands to gain
epinephrine auto-injector manufacturers (e.g., Mylan/Viatris, Kaleo, Auvi-Q); medical device suppliers and distributors; law enforcement training providers and consultants